Monday, November 23, 2020

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Cancer shared this article with you from Inoreader
Condition:   Hepatocellular Carcinoma Interventions:   Drug: IBI318;   Procedure: cTACE;   Drug: placebo Sponsor:   Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
View on the web

No comments:

Post a Comment

Collaboration request

Hi there How would you like to earn a 35% commission for each sale for life by selling SEO services Every website owner requires the ...